NASDAQ · RGNX
REGENXBIO Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RGNX: Nov 05, 2026
REGENXBIO Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.35. The reported EPS for the same quarter last year was $-1.2.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.35 | $-1.20 | $-1.63 | 5 |
| Dec 2026 | $-1.13 | $-1.01 | $-1.29 | 4 |
| Mar 2027 | $-1.04 | $-0.99 | $-1.09 | 2 |
| Jun 2027 | $-0.98 | $-0.92 | $-1.03 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · Fintel · BNK Invest- Zacks · Oct 29, 9:00 AM EDTRegenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketBeat · Oct 21, 5:02 PM EDTREGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene TherapyREGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives. Th
- Fintel · Oct 5, 9:54 PM EDTMizuho Initiates Coverage of REGENXBIO at OutperformFintel reports that on October 5, 2026, Mizuho initiated coverage of REGENXBIO (NASDAQGS:RGNX) (DB:RB0) with a Outperform recommendation.REGENXBIO Inc. is a biotechnology company based in the United States, operating within the biopharmaceutical sector. The company is primarily f
- BNK Invest · Aug 28, 3:38 PM EDTFriday 8/28 Insider Buying Report: RGNX, KDPBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- Barchart · Aug 25, 2:26 PM EDTStock Indices Finish Mostly Lower on Chipmaker WeaknessThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.28% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.97%. E-mini S&P futures (ESU26 ) fell -0.27%, and September E-mini…
- Zacks · Aug 25, 11:07 AM EDTRGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene TherapyREGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
- Barchart · Aug 24, 6:03 PM EDTRout in Chipmakers Weighs on Broader MarketThe S&P 500 Index ($SPX ) (SPY ) is down by -0.27% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.00%. E-mini S&P futures (ESU26 ) are down -0.26%, and September E-mini…
- Barchart · Aug 24, 5:54 PM EDTStocks Pressured by Weakness in Chipmakers and AI-Infrastructure StocksThe S&P 500 Index ($SPX ) (SPY ) is down by -0.43% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.41%. E-mini S&P futures (ESU26 ) are down -0.36%, and September E-mini…
- RTTNews · Aug 24, 9:37 AM EDTRegenxbio's RGX-121 Placed On FDA Clinical Hold After Spine MRI Findings In Hunter Syndrome Study(RTTNews) – Regenxbio Inc. (RGNX), a biotech company focused on developing curative gene therapy, on Monday announced that the U.S. FDA has placed a clinical hold on RGX-121, an investigational gene therapy for Hunter syndrome.
- MarketBeat · Aug 7, 7:03 AM EDTREGENXBIO Q2 Earnings Call HighlightsREGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of
- Zacks · Aug 6, 9:50 AM EDTRegenxbio (RGNX) Beats Q2 Earnings and Revenue EstimatesRegenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for REGENXBIO Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.